Black HR, Elliott WJ, Neaton JD.
et al. for the CONVINCE Research Group. Rationale and design for the Controlled Onset Verapamil Investigation
of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials.1998;19:370-390.
Black HR, Elliott WJ, Neaton JD.
et al. Baseline characteristics and early blood pressure control in the CONVINCE
Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews
of trials. J Clin Epidemiol.1995;48:23-40.
Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. Meta-analysis of the morning excess of acute myocardial infarction
and sudden cardiac death. Am J Cardiol.1997;79:1512-1516.
Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke.1998;29:992-996.
White WB, Anders RJ, MacIntyre JM.
et al. Nocturnal dosing of a novel delivery system of verapamil for systemic
hypertension. Am J Cardiol.1995;76:375-380.
White WB, Black HR, Weber MA, Elliott WJ, Bryzinski B, Fakouhi TD. Comparison of effects of COER-verapamil at bedtime and nifedipine GITS
on arising on early morning blood pressure, heart rate and the heart rate
blood pressure product. Am J Cardiol.1998;81:424-431.
Gupta SK, Yih MY, Atkinson L, Longstreth J. The effect of food, time of dosing, and body position on the pharmacokinetics
and pharmacodynamics of verapamil and norverapamil. J Clin Pharmacol.1995;35:1083-1093.
Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika.1983;70:659-663.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics.1979;35:549-556.
Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000:170-179.
Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation
of new treatments, part 2: practical issues and specific cases. Ann Intern Med.2000;133:464-470.
Gomberg-Maitland M, Baran DA, Fuster V. Treatment of congestive heart failure: guidelines for the primary care
physician and the heart failure specialist. Arch Intern Med.2001;161:342-352.
Danish Study Group on Verapamil in Myocardial Infarction (DAVIT-I). Verapamil in acute myocardial infarction. Eur Heart J.1984;5:516-528.
Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial
infarction: the Danish Verapamil Infarction Trial II (DAVIT-II). Am J Cardiol.1990;66:779-785.
Addonizio Jr VP, Fisher CA, Strauss 3rd JF, Wachtfogel YT, Colman RW, Josephson ME. Effects of verapamil and diltiazem on human platelet function. Am J Physiol.1986;250:H366-H371.
Lacoste L, Lam JY, Hung J, Waters D. Oral verapamil inhibits platelet thrombus formation in humans. Circulation.1994;89:630-634.
Ding YA, Chou TC, Lin KC. Effects of long-acting propranolol and verapamil on blood pressure,
platelet function, metabolic and rheological properties in hypertension. J Hum Hypertens.1994;8:273-278.
He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized
clinical trials. JAMA.1998;280:1930-1935.
Hansson L, Hedner T, Lund-Johansen P.
et al. Randomised trial of effects of calcium antagonists compared with diuretics
and β-blockers on cardiovascular morbidity and mortality in hypertension:
the Nordic Diltiazem (NORDIL) Study. Lancet.2000;356:359-365.
Blood Pressure Lowering Treatment Trialists' Collaborative. Effects of ACE-inhibitors, calcium antagonists, and other blood-pressure-lowering
drugs: results of prospectively designed overviews of randomised trials. Lancet.2000;356:1955-1964.
Smolensky MH, Portaluppi F. Chronopharmacology and chronotherapeutics of cardiovascular medications:
relevance to prevention and treatment of coronary heart disease. Am Heart J.1999;137:S14-S24.
The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on
death from cardiovascular causes, myocardial infarction, and stroke in high-risk
patients. N Engl J Med.2000;342:145-153.
ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to
doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment
to prevent Heart Attack Trial (ALLHAT). JAMA.2000;283:1967-1975.
Staessen JA, Fagard R, Thijs L.
et al. for the Systolic Hypertension Europe (Syst-EUR) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on
Isolated Systolic Hypertension in the Elderly. Lancet.1997;350:757-764.
Agodoa LY, Appel L, Bakris GL.
et al. for the African American Study of Kidney Disease and Hypertension (AASK)
Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive
nephrosclerosis: a randomized controlled trial. JAMA.2001;285:2719-2728.
Lewis EJ, Hunsicker LG, Clarke WR.
et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan
in patients with nephropathy due to type 2 diabetes. N Engl J Med.2001;345:851-860.
Brenner BM, Cooper ME, de Zeeuw D.
et al. for the Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus
with the Angiotensin II Antagonist Losartan (RENAAL) Study Group. Effects of losartan on renal and cardiovascular outcomes in patients
with type 2 diabetes and nephropathy. N Engl J Med.2001;345:861-869.
ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting
enzyme inhibitor or calcium channel blocker vs diuretic: Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA.2002;288:2981-2997.
The Sixth Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med.1997;157:2413-2446.